Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors.
Johannes, J.W., Bates, S., Beigie, C., Belmonte, M.A., Breen, J., Cao, S., Centrella, P.A., Clark, M.A., Cuozzo, J.W., Dumelin, C.E., Ferguson, A.D., Habeshian, S., Hargreaves, D., Joubran, C., Kazmirski, S., Keefe, A.D., Lamb, M.L., Lan, H., Li, Y., Ma, H., Mlynarski, S., Packer, M.J., Rawlins, P.B., Robbins, D.W., Shen, H., Sigel, E.A., Soutter, H.H., Su, N., Troast, D.M., Wang, H., Wickson, K.F., Wu, C., Zhang, Y., Zhao, Q., Zheng, X., Hird, A.W.(2017) ACS Med Chem Lett 8: 239-244
- PubMed: 28197319 
- DOI: 10.1021/acsmedchemlett.6b00464
- Primary Citation of Related Structures:  
5KU9, 5MES, 5MEV - PubMed Abstract: 
Mcl-1 is a pro-apoptotic BH3 protein family member similar to Bcl-2 and Bcl-xL. Overexpression of Mcl-1 is often seen in various tumors and allows cancer cells to evade apoptosis. Here we report the discovery and optimization of a series of non-natural peptide Mcl-1 inhibitors ...